Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: A multicenter, randomized, crossover trial

Headache

Volumn 43, Issue 8, 2003, Pages 835-844

  Di Monda, Vincenzo ^a   Nicolodi, Maria ^a   Aloisio, Antonina ^b   Del Bianco, Pierluigi ^a   Fonzari, Marco ^c   Grazioli, Irene ^d   Uslenghi, Carla ^d   Vecchiet, Leonardo ^e   Sicuteri, Federigo ^a,d  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d Solvay Pharma SpA   (Italy)

^e Solvay Pharma SpA ^*

Author keywords

Caffeine; Indomethacin; Migraine; Prochlorperazine; Sumatriptan

Indexed keywords

ANTIMIGRAINE AGENT; DIFMETREMITE; INDOMETACIN PLUS PROCHLORPERAZINE DIMALEATE PLUS CAFFEINE; SUMATRIPTAN SUCCINATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; EPILEPTIC AURA; FEMALE; GIRDLE SENSATION; HEADACHE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SENSORY DYSFUNCTION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUPPOSITORY; VERTIGO;

ACUTE DISEASE; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIEMETICS; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DRUG COMBINATIONS; FEMALE; HUMANS; INDOMETHACIN; MALE; MIGRAINE DISORDERS; PROCHLORPERAZINE; RECURRENCE; RESEARCH DESIGN; SEROTONIN AGONISTS; SUMATRIPTAN; SUPPOSITORIES; TREATMENT OUTCOME;

EID: 0042237034     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.2003.03161.x     Document Type: Article

References (33)

1. Sicuteri F, Nicolodi M. La tesi olistica dell'emicrania. [The holistic hypothesis of migraine.] Ann Ital Med Int. 1997; 12(suppl 1):3S-32S.
2. Hu XH, Tang HW, Li QS, Huang XF. Central mechanism of indomethacin analgesia. Eur J Pharmacol. 1994;263:53-57.
3. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7): 1-96.
4. Antonaci F, Pareja JA, Caminero AB, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua. Parenteral indomethacin: the "indotest." Headache. 1998;38:122-128.
5. Ivanez V, Soler R, Barreiro P. Hypnic headache syndrome: a case with good response to indomethacin. Cephalalgia. 1998;18:225-226.
6. Solomon S, Newman LC. Chronic daily bilateral headache responsive to indomethacin. Headache. 1999;39:754-757.
7. Rozen TD. LASH: a syndrome of long-lasting autonomic symptoms with hemicrania (a new indomethacin-responsive headache). Headache. 2000;40:483-486.
8. Dodick DW, Jones JM, Capobianco DJ. Hypnic headache: another indomethacin-responsive headache syndrome? Headache. 2000;40:830-835.
9. Hannerz J. Chronic bilateral headache responding to indomethacin. Headache. 2000;40:840-843.
10. Jones EB, Gonzales ER, Boggs JG, Grillo JA, Elswick RK. Safety and efficacy of rectal prochlorperazine for the treatment of migraine in the emergency department. Ann Emerg Med. 1994;24:237-241.
11. Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med. 1995;26:541-546.
12. US Headache Consortium. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. 2000. Available at: http://www.aan.com/public/ practiceguidelines/03.pdf. Accessed March 5, 2002.
13. Ghelardini C, Galeotti N, Di Cesare Mannelli L, Uslenghi C, Grazioli I, Bartolini A. Investigation into the analgesic effect of prochlorperazine. Presented in part at: the 30th Annual Meeting Society for Neuroscience; November 2000; New Orleans, La.
14. Ghelardini C, Galeotti N, Bartolini A. Caffeine induces central cholinergic analgesia. Naunyn Schmiedebergs Arch Pharmacol. 1997;356:590-595.
15. Ward N, Whitney C, Avery D, Dunner D. The analgesic effects of caffeine in headache. Pain. 1991;44: 151-155.
16. Laska EM, Sunshine A, Mueller F, Elvers WB, Siegel C, Rubin A. Caffeine as an analgesic adjuvant. JAMA. 1984;251:1711-1718.
17. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358:1668-1675.
18. Tfelt-Hansen P, Teall J, Rodriguez F, et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache. 1998;38:748-755.
19. Goldstein J, Ryan R, Jiang K, et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Headache. 1998;38:737-747.
20. 1B/1D agonist, compared with sumatriptan 100 mg. Headache. 1998;38:377-378.
21. Gallagher RM, Dennish G, Spierings EL, Chitra R. A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache. 2000;40:119-128.
22. Goadsby PJ, Ferrari MD, Olesen J, et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. Neurology. 2000;54:156-163.
23. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet. 1995;346:923-926.
24. Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol. 1991;31:295-299.
25. International Headache Society Committee on Clinical Trials Migraine. Guidelines for controlled trials of drugs in migraine: first edition. Cephalalgia. 1991;11:1-12.
26. Tfelt-Hansen P, Block G, Dahlöf C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia. 2000;20:765-786.
27. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000;60:1259-1287.
28. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache. 1999;39(suppl 2):20-26.
29. Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia. 2000;20:554-560.
30. th International Headache Research Seminars. Headache treatment, Trial Methodology, and New Drugs. New York: Lippincott-Raven; 1997:157-160.
31. Dahlof CG, Lipton RB, McCarroll KA, Kramer MS, Lines CR, Ferrari MD. Within-patient consistency of response of rizatriptan for treating migraine. Neurology. 2000;55:1511-1516.
32. Pascual J, Falk RM, Piessens F, et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large randomized, double-blind, placebo-controlled study. Cephalalgia. 2000;20:588-596.
33. Tepper SJ, Cochran A, Hobbs S, Woessner M. Sumatriptan suppositories for the acute treatment of migraine. Int J Clin Pract. 1998;52:31-35.